Patent · US Active

IL-IR-I binding polypeptide

US12116397B2 · kind B2 · utility

0Cited by

1References

25Claims

0Family size

Assignee

SWEDISH ORPHAN BIOVITRUM AG · SE

Inventors

Joachim Feldwisch · Tyresö, SE
Malin Lindborg · Boo, SE
Joakim Nilsson · Danderyd, SE
Erik Nordling · Danderyd, SE
Robert Svensson · Loftahammar, SE

Key dates

Filing date	Apr 3, 2018
Grant date	Oct 15, 2024
Priority date	—
Expiry date	Mar 12, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/31
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure relates to a class of engineered polypeptides having a binding affinity for interleukin-1 receptor type-I (IL-1R-I) which comprise the binding motif (BM) EX2X3X4X5X6X7EIX10X11LPNLX16RX18QYX21AFIX25X26LX28D. The present disclosure also relates to the use of such an IL-1R-I binding polypeptide as a therapeutic, prognostic and/or diagnostic agent.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.